Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Authors
Keywords
-
Journal
LANCET
Volume 398, Issue 10306, Pages 1157-1169
Publisher
Elsevier BV
Online
2021-09-09
DOI
10.1016/s0140-6736(21)00889-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
- (2021) Hilma J. van der Horst et al. Blood Cancer Journal
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
- (2020) Patrick J. Engelberts et al. EBioMedicine
- Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
- (2019) Tania Jain et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
- (2019) Pavel Klener INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
- (2019) Francisco‐Javier Peñalver et al. Cancer Medicine
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
- (2017) Gustaaf W. van Imhoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
- (2017) Ronald L Van Heertum et al. Drug Design Development and Therapy
- Hematopoietic Cell Transplantation for B-Cell Lymphoma: An Update
- (2017) Ernesto Ayala Cancer Control
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
- (2016) V. Jurinovic et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
- (2016) Y. Yuan et al. CLINICAL CANCER RESEARCH
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
- (2013) Raymund Buhmann et al. Journal of Translational Medicine
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma
- (2008) Tanya M. Wildes et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
- (2008) A. Martin et al. HAEMATOLOGICA
- Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
- (2008) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started